Akademik Veri Yönetim Sistemi
Interdisciplinary Cancer Research, Nima Rezaei, Editör, Springer, London/Berlin , Basel, ss.1-14, 2024
Radiomic analysis, which has developed rapidly in recent years, has become extremelypopular as a promising subject for the future. Radiomic data obtained from prostate-specific membrane antigen positron emission tomography/computed tomography(PSMA-PET/CT), prostate-specific membrane antigen positron emissiontomography/magnetic resonance (PSMA-PET/MR), ultrasonography (USG),sonoelastography, computed tomography (CT), CT perfusion images, andmultiparametric magnetic resonance imaging (mpMRI), which is the most frequentlyused imaging technique in prostate cancer, have been evaluated in various studies. The radiomic data obtained from the prostate gland and/or tumour has been used alone orcombined with clinical, genomic, epigenomic, transcriptomic, proteomic, and metabolicdata, and models have been developed through interpretation with artificial intelligence–supported statistical methods. It has been attempted to associate the developed modelswith many parameters such as Gleason Score prediction, prostate imaging-reporting anddata system (PI-RADS) prediction, clinically important prostate cancer diagnosis,differentiation of benign and malignant lesions, prediction of low and high-risk lesions,prediction of extra-prostatic extension, follow-up of patients under active observation,need for repeated biopsy, prediction of treatment efficacy, overall survival prediction,biochemical recurrence prediction, metastatic progression risk prediction, prediction oftoxicity developing associated with radiotherapy, and prediction of the need for adjuvantradiotherapy and androgen deprivation therapy (ADT). Despite the rapid and successfulresults, there is a need for the automisation of prostate gland segmentation and thestandardisation of radiomic signatures obtained and the models developed, and for thesestudies to be confirmed with large data sets. With increasing experience in these fieldsand completion of deficiencies, it is expected that radiogenomic approaches will have animportant place in clinical practice in the not too distant future.